|
Roche’s Skin Cancer Treatment Delayed by UK Drug-Cost Agency
Roche Holding will have to provide more information about the expense of the Zelboraf skin-cancer treatment before the UK’s drug-cost agency will decide whether to recommend use in the National Health Service.
Businessweek |
Register Now
Archives